农夫山泉(09633)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09633 农夫山泉

已收盘 10-20 16:08:20

41.880

+0.680

+1.65%

最高42.560	最低41.160	成交量616.02万
今开41.580	昨收41.200	日振幅3.40%
总市值4,710亿	流通市值2,109亿	总股本112.46亿
成交额2.59亿	换手率0.12%	流通股本50.35亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09633","market":"HK","secType":"STK","nameCN":"农夫山泉","latestPrice":41.88,"timestamp":1792483700006,"preClose":41.2,"halted":0,"volume":6160230,"delay":0,"changeRate":0.01650485436893203,"floatShares":5034666400,"shares":11246000000,"eps":1.6590548121522246,"marketStatus":"已收盘","change":0.68,"latestTime":"10-20 16:08:20","open":41.58,"high":42.56,"low":41.16,"amount":258855528,"amplitude":0.033981,"askPrice":41.88,"askSize":35200,"bidPrice":41.86,"bidSize":400,"shortable":3,"etf":0,"ttmEps":1.7912524384030388,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792546200000},"marketStatusCode":5,"adr":0,"listingDate":1599494400000,"exchange":"SEHK","adjPreClose":41.2,"dividendRate":0.026956,"openAndCloseTimeList":[[1792459800000,1792468800000],[1792472400000,1792483200000]],"volumeRatio":1.121138,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"NFU.HK","impliedVol":0.3072,"impliedVolPercentile":0.4},"requestUrl":"/m/hq/s/09633/tweets","defaultTab":"tweets","newsList":[{"id":"2676658857","title":"【券商聚焦】中信证券：Q3大众品需求触底企稳 但环比未看到明显复苏","url":"https://stock-news.laohu8.com/highlight/detail?id=2676658857","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676658857?lang=zh_cn&edition=full","pubTime":"2026-10-20 09:09","pubTimestamp":1792458541,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券表示，在2026Q2需求走弱的背景下，2026Q3大众品需求触底企稳，但环比未看到明显复苏。成本端，26Q3生鲜乳、大豆、PET等核心原材料价格有所上涨，部分企业通过提价减促等方式对冲。费用端，除了乳企预计将受到大型赛事费用确认影响，其余板块费用预计维持稳定。近期大众品板块股价调整较多，估值和股息优势凸显。推荐：1）供给侧维度，原奶周期触底上行有望推动乳品板块基本面未来几年上行；2）细分板块景气度，推荐量贩零食景气逆势提升的龙头企业；以及健康功能维度的企业；3）低估值、稳健型的龙头企业；4）高股息维度企业。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993935","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","LU1102505762.USD","00291","LU1064131003.USD","BK0012","LU1769817179.HKD","BK0276","IE0032834883.USD","01876","00168","LU0877626530.USD","LU0650527681.SGD","LU1064130708.USD","LU2148510915.USD","LU1515016050.SGD","LU2289578879.USD","SG9999001903.USD","HK0000306685.HKD","06186","IE00B031HY20.USD","HK0000320223.HKD","KCE","LU0211977185.USD","00322","80291","06030","IE00B0169L03.USD","LU0405327148.USD","LU0029875118.USD","LU0702159699.USD","LU0385154629.USD","09633","02319","LU1997245094.SGD","CRHKY","BK1564","00220","BK0188","LU0831093199.SGD","LU2045819591.USD","LU0048580855.USD","BK1604","HK0000306701.USD","IE0003895053.USD","BK1237","LU0359202008.SGD","09985","LU1115378108.SGD","600030","LU1997244956.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675595245","title":"万泰生物（603392）10月15日主力资金净买入174.64万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675595245","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675595245?lang=zh_cn&edition=full","pubTime":"2026-10-16 08:16","pubTimestamp":1792109779,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月15日收盘，万泰生物报收于25.3元，上涨0.4%，换手率0.44%，成交量5.5万手，成交额1.39亿元。近5日资金流向一览见下表：万泰生物融资融券信息显示，融资方面，当日融资买入598.63万元，融资偿还1338.39万元，融资净偿还739.76万元。万泰生物主营业务：体外诊断试剂、体外诊断仪器与疫苗的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600007147.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","BK1200","BK1589","BK0239","LU1981816686.USD","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675396861","title":"万泰生物（603392）10月13日主力资金净卖出944.05万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675396861","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675396861?lang=zh_cn&edition=full","pubTime":"2026-10-14 08:30","pubTimestamp":1791937854,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，万泰生物报收于25.74元，下跌2.17%，换手率0.42%，成交量5.3万手，成交额1.37亿元。近5日资金流向一览见下表：万泰生物融资融券信息显示，融资方面，当日融资买入852.95万元，融资偿还1526.37万元，融资净偿还673.42万元。万泰生物主营业务：体外诊断试剂、体外诊断仪器与疫苗的研发、生产及销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400007292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1200","BK0239","LU1981816686.USD","603392","BK1589","09633"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675369921","title":"股市必读：万泰生物新发布《万泰生物关于公司冻干重组呼吸道合胞病毒疫苗（CHO细胞）获得药物临床试验批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675369921","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675369921?lang=zh_cn&edition=full","pubTime":"2026-10-14 01:38","pubTimestamp":1791913090,"startTime":"0","endTime":"0","summary":"截至2026年10月13日收盘，万泰生物报收于25.74元，下跌2.17%，换手率0.42%，成交量5.3万手，成交额1.37亿元。公司公告汇总：万泰生物全资子公司冻干重组呼吸道合胞病毒疫苗获国家药监局临床试验批准，拟用于预防60岁及以上人群RSV所致下呼吸道疾病。公司高度重视人工智能技术与疫苗研发的深度融合。感谢您对公司的关注。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400001579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1981816686.USD","BK1200","BK1589","09633","159646","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675339464","title":"万泰生物：依托平台集群叠加大数据与AI工具实现新型疫苗抗原自主设计","url":"https://stock-news.laohu8.com/highlight/detail?id=2675339464","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675339464?lang=zh_cn&edition=full","pubTime":"2026-10-13 15:34","pubTimestamp":1791876888,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)10月13日在投资者关系平台上答复投资者关心的问题。投资者提问：请问邱总：请介绍一下，公司为生物疫苗人工智能究竟做了哪些具体性实质性的工作？万泰生物回复：您好！公司高度重视人工智能技术与疫苗研发的深度融合。在研发环节，依托公司搭建的覆盖疫苗研发全周期的抗原设计与临床前评价平台集群，叠加大数据与AI工具，实现新型疫苗抗原自主设计、专利壁垒突破和多维度临床前有效性验证，从源头提升创新疫苗管线临床申报转化率和商业化落地可行性。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300020593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","BK1589","LU1981816686.USD","603392","BK0239","159646","159739","BK1200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674387302","title":"万泰生物：鼻喷新冠、二价 HPV 存货计提是外部市场环境变化、供需格局变动带来的经营风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2674387302","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674387302?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:18","pubTimestamp":1791796690,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物10月12日在投资者关系平台上答复投资者关心的问题。还有戊肝疫苗，5亿的研发成本，卖出不到100万剂。鼻喷新冠、二价 HPV 存货计提是外部市场环境变化、供需格局变动带来的经营风险；水痘疫苗项目仍在推进；戊肝疫苗作为全球首创产品，市场培育周期较长。公司重大项目均履行相应审议决策流程，管理层对公司经营承担勤勉尽责责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200022630.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","603392","LU1981816686.USD","BK1200","BK1589","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674873073","title":"万泰生物：公司海外业务主要以美元作为计价结算币种","url":"https://stock-news.laohu8.com/highlight/detail?id=2674873073","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674873073?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:18","pubTimestamp":1791796688,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)10月12日在投资者关系平台上答复投资者关心的问题。投资者提问：请问：公司与泰国印尼等国家的收费是以人民币、美元还是当地货币结算，结算周期一般多长时间？谢谢。万泰生物回复：您好！公司海外业务主要以美元作为计价结算币种，结算周期根据不同业务模式有所区分。公司高度重视海外回款风险，通过投保出口信用保险、前置客户资质尽调、审慎选择合作方、合理约定付款条款、动态跟踪回款进度等方式保障海外收款安全。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200022626.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","09633","BK1200","BK0239","BK1589","LU1981816686.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674287302","title":"万泰生物：公司后续会加强投资者沟通","url":"https://stock-news.laohu8.com/highlight/detail?id=2674287302","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674287302?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:18","pubTimestamp":1791796688,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物10月12日在投资者关系平台上答复投资者关心的问题。在遵守信息披露监管要求的前提下，公司后续会加强投资者沟通。公司管理层将持续深耕主业，扎实做好经营，力争以长期业绩回报投资者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200022628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","BK1200","BK1589","09633","LU1981816686.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674873046","title":"万泰生物：越南是公司HPV疫苗国际化布局的目标市场之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2674873046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674873046?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:18","pubTimestamp":1791796686,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)10月12日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，与我国接壤的越南，人口大国且经济情况良好，为何至今贵司的HPV疫苗还没有进入该国？ 是在准入方面遇到了困难了吗？万泰生物回复：您好！越南是公司HPV疫苗国际化布局的目标市场之一。但国际上各个国家的药品监管要求不同，准入时间周期也不同。根据越南当地药品监管要求，目前相关注册准入工作正按计划有序推进。公司将严格按照监管要求及时履行信息披露义务。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200022625.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0239","603392","BK1200","LU1981816686.USD","09633","BK1589","FVNmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674873117","title":"万泰生物：公司有梅毒快速检测试剂盒相关产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2674873117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674873117?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:09","pubTimestamp":1791796152,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)10月12日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，目前有媒体报道了国外某国的梅毒激增，贵公司是否有生产梅毒快速检测试剂盒？目前梅毒快速试剂检测是否会出口？今年1至9月，贵公司的梅毒快速试剂检测盒的销量是否同比增长？谢谢万泰生物回复：您好！公司有梅毒快速检测试剂盒相关产品，该产品可对外出口。公司各类梅毒检测试剂包含化学发光、酶免、胶体金（快速检测）及质控品等多品类，产品出口覆盖亚、欧、非、拉美各大洲 20 多个国家和地区。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200022451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1200","BK1589","BK0239","LU1981816686.USD","09633","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674114873","title":"万泰生物：董事、高管减持属于个人财产安排","url":"https://stock-news.laohu8.com/highlight/detail?id=2674114873","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674114873?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:09","pubTimestamp":1791796150,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)10月12日在投资者关系平台上答复投资者关心的问题。投资者提问：公司股价跌跌不休，屡创新低。身为管理层，非但不关心股价，不维护市值，反而在此时落井下石，刻意通过二级市场减持，严重影响了公司在资本市场的形象和口碑。公司对于这样的人员有何惩罚措施？万泰生物回复：您好！股价受多重因素影响。董事、高管减持属于个人财产安排，减持全过程符合监管规定，且已依规履行信息披露义务。管理层将持续聚焦主业，努力改善经营，维护股东长期利益。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200022449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","LU1981816686.USD","BK1200","09633","BK1589","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674873161","title":"万泰生物：梅毒诊断试剂暂未在日本实现销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2674873161","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674873161?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:06","pubTimestamp":1791795967,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)10月12日在投资者关系平台上答复投资者关心的问题。投资者提问：请问：目前日本梅毒爆发，公司的梅毒诊断试剂在日本有销售布局吗？出口日本的量大吗？万泰生物回复：您好！目前公司在日本上市销售的为乙肝、丁肝、戊肝酶免检测试剂盒，梅毒诊断试剂暂未在日本实现销售。公司国际业务团队正密切关注日本梅毒市场动态，积极寻找合作伙伴，推进相关产品落地销售。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200022368.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","LU1981816686.USD","BK1200","BK0239","BK1589","09633"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674270708","title":"万泰生物(603392.SH)：冻干重组呼吸道合胞病毒疫苗(CHO细胞)获批临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2674270708","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674270708?lang=zh_cn&edition=full","pubTime":"2026-10-12 16:01","pubTimestamp":1791792078,"startTime":"0","endTime":"0","summary":"智通财经APP讯，万泰生物(603392.SH)发布公告，近日，公司全资子公司万泰沧海收到国家药监局核准签发的冻干重组呼吸道合胞病毒疫苗(CHO细胞)的《药物临床试验批准通知书》。同意开展预防60岁及以上人群由呼吸道合胞病毒(RSV)感染引起的下呼吸道疾病的临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159646","PSYK","LU1981816686.USD","09633","BK1589","BK1200","BK0239","MDTX","BMED","IBBJ","603392","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674845670","title":"股市必读：万泰生物新发布《万泰生物关于全资子公司通过土耳其GMP符合性检查的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674845670","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674845670?lang=zh_cn&edition=full","pubTime":"2026-10-12 02:12","pubTimestamp":1791742334,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘，万泰生物报收于26.96元，上涨1.74%，换手率0.54%，成交量6.77万手，成交额1.8亿元。当日关注点交易信息汇总：10月9日主力资金净流出944.25万元，占总成交额5.26%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200000721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","09633","BK0239","BK1589","BK1200","LU1981816686.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674641850","title":"万泰生物（603392）披露全资子公司通过土耳其GMP符合性检查公告，10月09日股价上涨1.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674641850","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674641850?lang=zh_cn&edition=full","pubTime":"2026-10-09 22:23","pubTimestamp":1791555798,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘，万泰生物报收于26.96元，较前一交易日上涨1.74%，最新总市值为340.88亿元。近日，北京万泰生物药业股份有限公司全资子公司厦门万泰沧海生物技术有限公司的九价HPV疫苗生产线通过土耳其药品和医疗器械管理局GMP符合性检查，并获得TITCK颁发的GMP证书。此次通过检查标志着公司生产和质量管理体系首次通过PIC/S成员国的GMP符合性检查。PIC/S成员国间可实现GMP检查结果互认，但不构成市场准入或产品注册的自动批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900038416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","BK1589","603392","LU1981816686.USD","BK1200","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141190019","title":"异动解读｜农夫山泉盘中上涨3.21%，控股股东连续增持释放信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1141190019","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141190019?lang=zh_cn&edition=full","pubTime":"2026-10-09 13:31","pubTimestamp":1791523860,"startTime":"0","endTime":"0","summary":"10月9日，农夫山泉盘中上涨3.21%，报41.74港元，成交额1.54亿港元。消息面上，控股股东钟睒睒近期通过养生堂连续在二级市场增持公司H股，最新好仓比例升至64.41%。港交所披露显示，钟睒睒于9月17日至9月30日期间多次增持，买入均价介于38.68港元至39.48港元之间，累计增持规模涉及数千万元，最新持股量达32.43亿股。连续增持行为向市场传递了控股股东对公司长期价值的信心，对公司股价形成正面催化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09633"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673063771","title":"今日最佳：尖叫这双眼睛看得够远。","url":"https://stock-news.laohu8.com/highlight/detail?id=2673063771","media":"差评","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673063771?lang=zh_cn&edition=full","pubTime":"2026-10-07 00:00","pubTimestamp":1791302400,"startTime":"0","endTime":"0","summary":"来源小红书：@你的宝藏太权威了。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5NDc1NzQ4MA==&mid=2654700221&idx=3&sn=f454833ad884f7441180e72cb391dfa1&chksm=8a1298e0381650a8fcc55e1a3faffd772f78e4bfae47817a0193d5db53ba99aba289683354cc&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1200","09633","LU1981816686.USD","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123551511","title":"农夫山泉：钟睒睒增持，好仓比例升至64.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123551511","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123551511?lang=zh_cn&edition=full","pubTime":"2026-10-06 17:32","pubTimestamp":1791279149,"startTime":"0","endTime":"0","summary":"钟睒睒通过其全资控股的养生堂有限公司于2026年9月30日在联交所场内以每股均价39.4787港元买入农夫山泉H股股份14.62万股，涉资约577.18万港元，属场内主动交易，即在二级市场直接买卖股份。钟睒睒此次增持前持有农夫山泉好仓32.42亿股，占比64.4%；增持后持股量为32.43亿股，好仓比例升至64.41%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09633"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165953990","title":"农夫山泉9月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1165953990","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165953990?lang=zh_cn&edition=full","pubTime":"2026-10-02 20:11","pubTimestamp":1790943070,"startTime":"0","endTime":"0","summary":"农夫山泉股份有限公司于2026年10月2日发布截至2026年9月30日的股份变动月报表。报告期内，公司法定/注册股本合计为人民币1,124,646,640元，其中包括已发行H股普通股5,034,666,400股与内资股6,211,800,000股。报告显示，截至9月末，H股已发行股份维持在5,034,666,400股，内资股则维持在6,211,800,000股，均无新增发行、购回或注销情况。公司已确认满足香港联交所有关公眾持股量的要求，并提示H股上市时所要求的最低公眾持股量占比为14.11%。本次公告由执行董事及公司秘书韩林攸签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09633"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136560125","title":"农夫山泉：钟睒睒增持，好仓比例升至64.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1136560125","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136560125?lang=zh_cn&edition=full","pubTime":"2026-09-30 17:42","pubTimestamp":1790761337,"startTime":"0","endTime":"0","summary":"钟睒睒通过其全资控股的养生堂有限公司于2026年9月28日在联交所场内以每股均价39.37港元买入农夫山泉股份有限公司H股股份45万股，涉资约1771.65万港元，属场内主动交易，即在二级市场直接买卖股份。钟睒睒此次增持前持有农夫山泉好仓32.42亿股，占比64.39%；增持后持股量为32.42亿股，好仓比例升至64.4%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09633"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nongfuspring.com","stockEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":0.0462},{"period":"3month","weight":-0.0242},{"period":"6month","weight":-0.0835},{"period":"1year","weight":-0.228},{"period":"ytd","weight":-0.0968}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0153},{"period":"6month","weight":-0.0754},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":-0.0563}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"农夫山泉股份有限公司是一家主要从事生产及销售包装饮用水及饮料的中国公司。该公司通过五个分部运营。水类产品分部从事制造及销售天然包装饮用水。即饮茶类产品分部从事制造及销售即饮茶。功能饮料产品分部从事制造及销售功能饮料。果汁饮料产品分部从事制造及销售果汁饮料产品。其他产品分部从事制造及销售农产品及其他饮料。该公司主要在国内市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.003567},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.016331},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.07575},{"month":4,"riseRate":0.666667,"avgChangeRate":0.026458},{"month":5,"riseRate":0.666667,"avgChangeRate":0.019912},{"month":6,"riseRate":0.5,"avgChangeRate":-0.035833},{"month":7,"riseRate":0.833333,"avgChangeRate":0.029658},{"month":8,"riseRate":0.333333,"avgChangeRate":0.002159},{"month":9,"riseRate":0.5,"avgChangeRate":0.027679},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.042598},{"month":11,"riseRate":0.833333,"avgChangeRate":0.094346},{"month":12,"riseRate":0.666667,"avgChangeRate":0.06968}],"exchange":"SEHK","name":"农夫山泉","nameEN":"NONGFU SPRING"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"农夫山泉(09633)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供农夫山泉(09633)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"农夫山泉,09633,农夫山泉股票,农夫山泉股票老虎,农夫山泉股票老虎国际,农夫山泉行情,农夫山泉股票行情,农夫山泉股价,农夫山泉股市,农夫山泉股票价格,农夫山泉股票交易,农夫山泉股票购买,农夫山泉股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"农夫山泉(09633)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供农夫山泉(09633)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}